Dauntless Investment Group LLC Buys Shares of 191,822 INmune Bio, Inc. (NASDAQ:INMB)

Dauntless Investment Group LLC purchased a new stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 191,822 shares of the company's stock, valued at approximately $896,000. INmune Bio makes up about 0.9% of Dauntless Investment Group LLC's holdings, making the stock its 8th biggest position. Dauntless Investment Group LLC owned approximately 0.87% of INmune Bio at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Wells Fargo & Company MN grew its holdings in shares of INmune Bio by 51.0% during the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after purchasing an additional 2,155 shares during the last quarter. JPMorgan Chase & Co. increased its position in INmune Bio by 93.0% in the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock valued at $53,000 after acquiring an additional 5,461 shares in the last quarter. Mariner LLC bought a new position in shares of INmune Bio in the fourth quarter worth about $65,000. Financial Advocates Investment Management lifted its position in shares of INmune Bio by 14.8% during the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company's stock worth $72,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of INmune Bio by 16.9% during the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company's stock worth $78,000 after purchasing an additional 2,424 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Rodman & Renshaw began coverage on INmune Bio in a research report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price objective on the stock. RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a report on Tuesday, January 28th. Maxim Group raised their target price on shares of INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, Scotiabank increased their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a report on Tuesday, February 11th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $22.80.

INmune Bio Stock Performance

INMB traded down $0.09 on Tuesday, reaching $7.81. The company had a trading volume of 58,787 shares, compared to its average volume of 252,784. The stock has a market cap of $179.51 million, a P/E ratio of -3.57 and a beta of 1.86. INmune Bio, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $12.72. The company's fifty day moving average is $7.80 and its 200 day moving average is $6.73.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.14. On average, sell-side analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.